title: Helicobacter pylori infection and thrombocytopenia: a single-institution experience in Mexico.
abstract: The association between gastrointestinal H. pylori infection and thrombocytopenia was studied in a single institution in Mexico, over a 5-year period. In 99 individuals with H. pylori infection, the prevalence of thrombocytopenia was 14%, whereas in 23 consecutive patients with chronic refractory thrombocytopenic purpura, the prevalence of H. pylori infection was 60%, this figure being similar to that informed in the general population of Mexico (66%); the association between thrombocytopenia and H. pylori infection was not significant. In 14 patients who were found to have both thrombocytopenia and H. pylori infection, eradication treatment was given and the platelet count recovered in three. It is not still clear if detection of H. pylori infection should be routinely included in the initial workup of chronic thrombocytopenia.
authors.affiliation: Laboratorios Clínicos de Puebla.
authors.forename: Roberto A
authors.initials: RA
authors.lastname: Estrada-Gómez
authors.forename: Israel
authors.initials: I
authors.lastname: Parra-Ortega
authors.forename: Carlos
authors.initials: C
authors.lastname: Martínez-Barreda
authors.forename: Guillermo J
authors.initials: GJ
authors.lastname: Ruiz-Argüelles
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001729:Bismuth / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D015897:Comorbidity; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000077402:Pantoprazole; D010976:Platelet Count; D015995:Prevalence; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000453:epidemiology / Q000382:microbiology; D012074:Remission Induction; D012459:Salicylates / Q000008:administration & dosage / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000453:epidemiology* / Q000382:microbiology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D000658:Amoxicillin; D000077402:Pantoprazole; D017291:Clarithromycin; D001729:Bismuth